BlackRock Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

BlackRock Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$8.72M	Sell	1,254,165 -27,705	-2%	-$191K	0.01%	937
2016 Q3	$10.6M	Buy	1,281,870 +1,217,515	+1,892%	+$10.3M	0.01%	840
2016 Q2	$521K	Sell	64,355 -6,427	-9%	-$40.4K	﹤0.01%	2097
2016 Q1	$360K	Hold	70,782	–	–	﹤0.01%	2245
2015 Q4	$546K	Sell	70,782 -8,882	-11%	-$61.6K	﹤0.01%	2031
2015 Q3	$459K	Sell	79,664 -68,572	-46%	-$534K	﹤0.01%	2255
2015 Q2	$1.36M	Buy	148,236 +64,450	+77%	+$719K	﹤0.01%	1457
2015 Q1	$1.01M	Buy	+83,786	New	+$944K	﹤0.01%	1552

Other funds holding IOVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Advisors's IOVA Position: Q4 2016 in Review

BlackRock Advisors reduced its Iovance Biotherapeutics (IOVA) stake by 2.2% in Q4 2016, selling an estimated $191K and leaving 1,254,165 shares worth $8.72M. The position accounts for 0.01% of the portfolio, ranked #937.

BlackRock Advisors first reported a position in IOVA in Q1 2015 and has held it in 8 quarters since. The position peaked at $10.6M in Q3 2016. 87 funds tracked by Wall St. Rank hold IOVA as of Q4 2016.

BlackRock Advisors held 1,254,165 shares of Iovance Biotherapeutics worth $8.72M as of Q4 2016.
BlackRock Advisors sold 27,705 Iovance Biotherapeutics shares in Q4 2016, an estimated $191K.
Iovance Biotherapeutics made up 0.01% of BlackRock Advisors's portfolio in Q4 2016, its #937 holding.
BlackRock Advisors first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 8 quarters since.
BlackRock Advisors's Iovance Biotherapeutics position peaked at $10.6M in Q3 2016.
87 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.